[e-med] Les traitements du SIDA rendent l'allaitement plus sûr

["remed" <c.bruneton@remed.org>]

[remerciement à C Rambert pour la traduction.CB]

Les traitements du SIDA rendent l'allaitement plus sûr
Reuters - Lun 4 février, 15:59 

WASHINGTON (Reuters) - Un médicament qui protège les enfants à la naissance
contre la contamination par le virus du SIDA peut aussi les protéger pendant
l'allaitement, comme annoncé ce lundi par des chercheurs.

Des enfants nés de mères infectées par le VIH, traitées par la névirapine
alors qu'elles allaitaient, semblent avoir moitié moins de risques d'être
infectés, ont annoncés des chercheurs pendant une réunion d'experts du SIDA
tenue à Boston.

La névirapine est largement employée pour protéger les bébés à la naissance.
Une dose unique administrée à la mère pendant le travail et au bébé à la
naissance réduit le risque de transmission de 47%.

Mais les enfants peuvent encore être infectés après la naissance par le lait
maternel, qui peut transmettre le virus. Dans de nombreux pays,
l'allaitement maternel est la seule option.

Le Dr. Brooks Jackson du Johns Hopkins University de Baltimore et des
collègues en Ethiopie, en Inde et en Ouganda ont voulu vérifier s'ils
pouvaient poursuivre le traitement sans risque pour les bébés pendant six
semaines.

Ainsi 2.000 bébés ont reçu soit de la névirapine soit une solution de
vitamines entre 2001 et 2007.

"A l'âge de six mois, chez des enfants qui avaient reçu un traitement de six
semaines, le risque d'infection par le VIH ou le décès étaient réduits d'un
tiers par opposition à ceux n'ayant reçu qu'une seule dose du traitement," a
déclaré Johns Hopkins (NDLR: il faut comprendre "le représentant du Johns
Hopkins").

L'OMS estime que 150,000 enfants sont infectés par le SIDA chaque année à la
suite d'allaitement. Globalement le virus mortel et incurable infecte 33
millions de personne.

La Névirapine est commercialisée par Boehringer Ingelheim sous le nom de
Viramune.

(Rapport de Maggie Fox, révisé par Will Dunham et Cynthia Osterman)


*****************
	
	HIV drugs make breast-feeding safer
	By Reuters - Mon Feb 4, 3:59 PM PST
	
	
	
	WASHINGTON (Reuters) - A drug that helps prevent babies from
catching the
	AIDS virus at birth can also protect them while nursing, researchers
	reported on Monday.
	
	Babies of HIV-infected women who were given the drug nevirapine
while they
	breast-fed were half as likely to become infected, the researchers
told a
	meeting in Boston of AIDS experts.
	
	Nevirapine is already widely used to protect babies at birth. A
single dose
	given to the mother as she goes into labor and to the baby at birth
cuts
	transmission by 47 percent.
	
	But babies continue to become infected after birth, via their
mothers'
	breast milk, which can carry the virus. In many developing countries
	breast-feeding is the only option.
	
	Dr. Brooks Jackson of Johns Hopkins University in Baltimore and
colleagues
	in Ethiopia, India and Uganda wanted to see if they could safely
continue
	giving the drug to babies for as long as six weeks.
	
	They gave 2,000 new babies either nevirapine or a vitamin solution
between
	2001 and 2007.
	
	"At 6 months of age, the risk of postnatal HIV infection or death in
infants
	who received the six-week regimen was almost one-third less than the
risk
	for infants given only a single dose," Johns Hopkins said in a
statement.
	
	The World Health Organization estimates that 150,000 infants are
infected
	with the AIDS through breast-feeding each year. The fatal and
incurable
	virus infects 33 million people globally.
	
	Nevirapine is sold under the brand name Viramune by privately held
	Boehringer Ingelheim.
	
	(Reporting by Maggie Fox, editing by Will Dunham and Cynthia
Osterman)
	
	
	******************
	
	
	CORRECTED: HIV drugs make breast-feeding safer
	
	By Reuters - Mon Feb 4, 3:53 PM PST
	
	
	
	Corrects second paragraph to show babies, not mothers, got the drug
and 6th
	paragraph to show babies got vitamins and not placebo.)
	
	WASHINGTON (Reuters) - A drug that helps prevent babies from
catching the
	AIDS virus at birth can also protect them while nursing, researchers
	reported on Monday.
	
	Babies of HIV-infected women who were given the drug nevirapine
while they
	breast-fed were half as likely to become infected, the researchers
told a
	meeting in Boston of AIDS experts.
	
	Nevirapine is already widely used to protect babies at birth. A
single dose
	given to the mother as she goes into labor and to the baby at birth
cuts
	transmission by 47 percent.
	
	But babies continue to become infected after birth, via their
mothers'
	breast milk, which can carry the virus. In many developing countries
	breast-feeding is the only option.
	
	Dr. Brooks Jackson of Johns Hopkins University in Baltimore and
colleagues
	in Ethiopia, India and Uganda wanted to see if they could safely
continue
	giving the drug to babies for as long as six weeks.
	
	They gave 2,000 new babies either nevirapine or a vitamin solution
between
	2001 and 2007.
	
	"At 6 months of age, the risk of postnatal HIV infection or death in
infants
	who received the six-week regimen was almost one-third less than the
risk
	for infants given only a single dose," Johns Hopkins said in a
statement.
	
	The World Health Organization estimates that 150,000 infants are
infected
	with the AIDS through breast-feeding each year. The fatal and
incurable
	virus infects 33 million people globally.
	
	Nevirapine is sold under the brand name Viramune by privately held
	Boehringer Ingelheim.
	
	(Reporting by Maggie Fox, editing by Will Dunham and Cynthia
Osterman)